Article Information
History
- June 21, 2022.
Article Versions
- Version 1 (June 17, 2022 - 10:12).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ana Bocanegra1,†,
- Gonzalo Fernández2,
- Daniel Ajona4,5,6,
- Hugo Arasanz3,
- Ester Blanco1,7,
- Miren Zuazo1,
- Luisa Chocarro1,
- Sergio Piñeiro-Hermida1,
- Pilar Morente1,
- Leticia Fernández1,
- Maider Garnica1,
- Ana Remirez4,
- Maite Martinez-Aguillo3,
- Idoia Morilla3,
- Beatriz Tavira4,8,9,
- Pablo Ramos2,
- Miriam Echaide2,
- Juan José Lasarte8,10,
- Luis Montuenga4,5,9,
- Ruth Vera3,
- Ruben Pio4,5,6,
- David Escors1,*,† and
- Grazyna Kochan1,*,†
- 1Oncoimmunology group, Navarrabiomed-IdISNA, Pamplona, Navarra, Spain.
- 2Medical Oncology Department, San Carlos Clinical Hospital, IdISSC, San Carlos Clinical Hospital Institute for Health Research, Madrid, Spain.
- 3Department of Oncology, Hospital Universitario de Navarra-IdISNA, Pamplona, Navarra, Spain.
- 4Program in Solid Tumors, CIMA-University of Navarre-IdISNA, Pamplona, Spain.
- 5CIBERONC, Centro de Investigación Biomédica en Red de Cáncer.
- 6Department of Biochemistry and Genetics, School of Sciences, University of Navarra-IdISNA, Pamplona, Spain.
- 7Program in Gene Therapy and Regulation of Gene Expression, CIMA-University of Navarra-IdISNA, Pamplona, Spain.
- 8Cancer Center University of Navarra (CCUN), Pamplona, Spain.
- 9Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra-IdISNA, Pamplona, Spain.
- 10Program in Immunology and Immunotherapy, CIMA-University of Navarra-IdISNA, Pamplona, Spain.
- ↵* Corresponding authors: grazyna.kochan{at}navarra.es; descorsm{at}navarra.es; ai.bocanegra.gondan{at}navarra.es
↵† These authors contributed equally to this work.